Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...

Hevia and Soussa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data ...

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) came out of the blocks strongly at the ESMO congress with ...

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...

Roche has taken a lead in the oral SERD category of breast cancer therapies with the presentation of new data at ESMO showing ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

In an era where the biopharmaceutical landscape is rapidly evolving, a comprehensive approach to demonstrating and ...

At this year’s European Society for Medical Oncology (ESMO) Annual Meeting, pharmaphorum web editor Nicole Raleigh spoke with ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

Johnson & Johnson has said it wants to spin off its orthopaedics division as part of an effort to redirect its business towards higher-growth areas. The announcement – made as the company raised its ...

One in six laboratory-confirmed bacterial infections in people worldwide in 2023 were resistant to antibiotic treatments, according to the WHO, which has urged greater efforts to tackle the issue. The ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that are ...